U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H10N2O4
Molecular Weight 198.176
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MIMOSINE

SMILES

N[C@@H](CN1C=CC(=O)C(O)=C1)C(O)=O

InChI

InChIKey=WZNJWVWKTVETCG-YFKPBYRVSA-N
InChI=1S/C8H10N2O4/c9-5(8(13)14)3-10-2-1-6(11)7(12)4-10/h1-2,4-5,12H,3,9H2,(H,13,14)/t5-/m0/s1

HIDE SMILES / InChI

Molecular Formula C8H10N2O4
Molecular Weight 198.176
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Mimosine or leucenol is an alkaloid, beta-3-hydroxy-4 pyridone amino acid. Mimosine is an effective inhibitor of DNA replication in mammalian cells. It blocks entry into S phase (late G1 phase), and suppress elongation of DNA replication (S phase). The chelation of iron seems to be one of the main modes of action of mimosine for cell cycle arrest. As an iron-chelating and cell cycle stopping agent, mimosine was tested in preclinical models of cancer, pulmonary fibrosis and iron overload.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
3.8 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
In model of pulmonary fibrosis mimosine was administed at doses 25 and 50 mg/kg. Pulmonary fibrosis was induced by tracheal instillation of 5 mg/kg bleomycin. Mimosine was first dissolved in Tris-buffer at pH 8.9, and then pH was adjusted to 7.2 with 1 N HCl. Before administration, this solution was freshly diluted by 0.9% physiologic saline to achieve the required concentration. L-Mimosine was administered via subcutaneous injection once daily from day 1 to day 28 after BLM or saline treatment.
Route of Administration: Other
In Vitro Use Guide
The effect of mimosine on asynchronously proliferating HeLa cells was analyzed by flow cytometry. HeLa-S3 cells were cultured as proliferating monolayers on 145-mm plates in DMEM, supplemented with 10% FCS, 10 U/ml penicillin, and 0.1 mg/ml streptomycin. Mimosine stock solution was prepared at 10 mM in DMEM and filtered through 20-mm filters. Synchronization of HeLa cells by mimosine was achieved by adding mimosine from the stock solution directly to the cells at the concentrations specified. Cell synchronization was determined by flow cytometry of isolated nuclei. One million nuclei were directly stained with propidium iodide (5 mg/ml in PBS containing 0.4% Triton X-100) and analyzed by FACScan (Becton Dickinson) using the Lysis II-software.
Substance Class Chemical
Record UNII
Z46B1LUI5N
Record Status Validated (UNII)
Record Version